id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342888-o7ezn9dd	Wang, Lei-Yun	Remdesivir and COVID-19	2020-10-01		.txt	text/plain	1221	75	55	Yeming Wang and colleagues 1 reported that the hazard of 28-day clinical improvement for 158 patients with severe COVID-19 randomly assigned to remdesivir was 1·2 times (95% CI 0·9 to 1·8) the hazard of patients randomly assigned to placebo, but the 28-day mortality in both these groups was similar. Additionally, Wang and colleagues 1 report that the effect of remdesivir on clinical improvement appeared stronger among patients who started treatment within 10 days of symptom onset than among those who started later. We appreciate the possible explanation raised by Lei-Yun Wang and colleagues that the genetic backgrounds of patients might be one of the reasons for discrepant results between the Chinese and American remdesivir clinical trials. Whether the different strains of severe acute respiratory syndrome coronavirus 2 between China and the USA contribute to the discrepant effect of remdesivir also needs to be confirmed.	./cache/cord-342888-o7ezn9dd.txt	./txt/cord-342888-o7ezn9dd.txt